Financial Performance - The company's revenue for Q3 2023 was ¥1,119,339,453.28, representing a decrease of 8.62% compared to the same period last year[6]. - Net profit attributable to shareholders was ¥169,794,466.01, down 14.30% year-on-year[6]. - The net profit after deducting non-recurring gains and losses was ¥165,401,354.72, a decrease of 12.17% compared to the previous year[6]. - Total operating revenue for the current period was ¥3,237,459,693.20, a decrease of approximately 6.2% from ¥3,452,994,013.86 in the previous period[28]. - Net profit for the current period was ¥471,952,130.64, a decrease of 11.4% compared to ¥532,732,088.05 in the previous period[28]. - Basic earnings per share for the current period was ¥0.4767, down from ¥0.5350 in the previous period[30]. - The company’s basic earnings per share for the period was ¥0.1716, reflecting a decrease of 14.33% year-on-year[6]. Assets and Liabilities - The total assets at the end of the reporting period were ¥7,003,008,069.03, an increase of 3.93% from the end of the previous year[6]. - Total liabilities increased to ¥1,300,040,340.72 from ¥1,230,731,357.94 in the previous period[28]. - Current assets totaled RMB 3,548,177,637.21, compared to RMB 3,434,294,202.63 in the same period last year, reflecting a growth of approximately 3.34%[22]. - Total liabilities were not explicitly stated, but current liabilities included accounts payable of RMB 311,119,961.38, up from RMB 273,117,753.80[22]. Equity - The equity attributable to shareholders increased to ¥5,657,624,670.16, up 3.67% from the end of the previous year[6]. - Total equity attributable to shareholders of the parent company was ¥5,657,624,670.16, an increase from ¥5,457,448,911.92 in the previous period[28]. Cash Flow - Cash flow from operating activities for the year-to-date was ¥489,132,192.50, showing a significant increase of 33.55%[6]. - Total cash inflow from operating activities was approximately CNY 2.83 billion, a decrease from CNY 3.09 billion in the previous year, representing a decline of 8.4%[36]. - Cash and cash equivalents at the end of the period totaled CNY 1.71 billion, up from CNY 1.08 billion at the end of the previous year[36]. - Operating cash flow net amount was CNY 489.13 million, an increase of 33.5% from CNY 366.27 million in the previous year[36]. - Cash paid for taxes was CNY 179.20 million, significantly lower than CNY 350.29 million in the previous year, showing a reduction of 48.9%[36]. Accounts Receivable and Inventory - The company reported a 60.42% decrease in accounts receivable compared to the beginning of the year, amounting to a reduction of ¥2,183,800[11]. - Accounts receivable increased to RMB 696,223,177.65 from RMB 553,595,447.76, marking a growth of approximately 25.7%[19]. - Inventory decreased to RMB 842,844,490.97 from RMB 890,504,897.05, indicating a reduction of about 5.36%[22]. Expenses - Total operating costs decreased to ¥2,682,439,708.51, down 5.2% from ¥2,829,066,325.19[28]. - Research and development expenses for the current period were ¥139,459,816.96, compared to ¥150,824,651.11 in the previous period, indicating a reduction of approximately 7.5%[28]. - The company reported a decrease in sales expenses to ¥726,839,396.07 from ¥1,001,037,722.42 in the previous period, reflecting a cost-cutting strategy[28]. Other Financial Metrics - The company’s weighted average return on equity was 3.07%, down 0.81% from the previous year[6]. - The company’s long-term equity investments increased to RMB 225,525,476.26 from RMB 211,741,711.88, reflecting a growth of approximately 6.5%[22]. - The company’s goodwill stood at RMB 585,778,085.98, up from RMB 573,266,905.88, indicating an increase of about 2.2%[22]. - Other comprehensive income after tax for the current period was ¥25,335,128.82, compared to a loss of ¥23,969,658.40 in the previous period[30]. Shareholder Information - The number of common shareholders at the end of the reporting period was 27,592, with the largest shareholder holding 21.55% of the shares[17]. Audit Status - The company has not undergone an audit for the third quarter report[39].
仙琚制药(002332) - 2023 Q3 - 季度财报